Abstract:Introduction: Adult growth hormone deficiency (AGHD) is associated with a high prevalence of metabolic syndrome (MS), which contributes to the unfavorable cardiovascular risk profile in these patients. Insulin like growth factor-1 (IGF-1) is a widely used biomarker, however it does not always reflect the cardiometabolic risk and has a poor relationship with clinical efficacy endpoints. Consequently, there is an unmet need for biomarkers to monitor responses to GH-replacement. Afamin is a hormone-like glycoprotein, expressed in the liver. Higher afamin levels are strongly associated with MS and insulin resistance (IR). Although both MS and IR are very common in AGHD, afamin has not been investigated in these patients. Purpose: To investigate afamin as a potential biomarker in patients with AGHD. Materials and methods: Participants included 20 AGHD patients (11 GH-substituted and 9 GH-unsubstituted) and 37 healthy controls. Subjects underwent routine laboratory examinations, anthropometric measurements, body composition analysis using multi-frequency bioelectrical impedance analysis (InBody720) and measurement of serum afamin concentrations. In GH-substituted subjects, GH-substitution was withdrawn for 2 months. Measurements were carried out right before GH-withdrawal, at the end of the 2-month withdrawal period, and 1 month after reinstituting GH-replacement therapy (GHRT). Results: GH-unsubstituted patients demonstrated higher afamin levels compared to controls (p=0.03). Afamin positively correlated with skeletal muscle mass, bone mineral content, total body water, extracellular- and intracellular water content, insulin (all, p<0.01), HOMA-IR (p=0.01) and C-peptide (p=0.03) levels in AGHD but not in healthy controls. In GH-substituted patients 2-month of GH-withdrawal caused significant changes in body composition, including decreased fat-free mass, skeletal muscle mass, total body water, and intracellular water content (all, p<0.01); but these changes almost fully recovered 1 month after reinstituting GHRT. Unexpectedly, afamin levels decreased after GH-withdrawal (p=0.03) and increased with reinstitution (p<0.01). Changes of afamin levels during GH-withdrawal positively correlated with changes of HOMA-IR (r=0.80; p<0.01) and changes of insulin (r=0.71; p=0.02). Conclusion: Higher afamin levels in unsubstituted AGHD patients might indicate severe metabolic dysregulation. Significant changes accompanying GH-withdrawal and reinstitution, along with strong correlations with measures of IR, suggest that afamin could be a promising biomarker to monitor GHRT-associated changes of insulin sensitivity.

Body Fat Distribution and Circulating Adipsin Are Related to Metabolic Risks in Adult Patients with Newly Diagnosed Growth Hormone Deficiency and Improve after Treatment

CORRELATION OF INCREASED SERUM ADIPSIN WITH INCREASED CARDIOVASCULAR RISKS IN ADULT PATIENTS WITH GROWTH HORMONE DEFICIENCY.

Circulating Acyl and Des-Acyl Ghrelin Levels in Obese Adults: a Systematic Review and Meta-Analysis

LIPID ACCUMULATION PRODUCT, VISCERAL ADIPOSITY INDEX, AND CHINESE VISCERAL ADIPOSITY INDEX AS MARKERS OF CARDIOMETABOLIC RISK IN ADULT GROWTH HORMONE DEFICIENCY PATIENTS: A CROSS-SECTIONAL STUDY.

Dynamic changes in the distribution of facial and abdominal adipose tissue correlated with surgical treatment in acromegaly

Correlation of Visceral Adipose Levels and Cardiovascular Risk Factors for Disease in Patients with Adult Growth Hormone Deficiency

Influence of Recombinant Human Growth Hormone on Lipid Metabolism and Adiponectin Levels in Children with Growth Hormone Deficiency

Association Between Serum Growth Hormone Levels and Nonalcoholic Fatty Liver Disease: a Cross-Sectional Study.

Changes in body proportions and body fat content in GH-deficient and non-GH-deficient children during the first year of growth hormone treatment

Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency

The comprehensive impact on human body induced by resolution of growth hormone excess.

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study

Truncal and Leg Fat Associations with Metabolic Risk Factors among Chinese Adults.

The role of IGF1 in determining body composition in children and adolescents with growth hormone deficiency and those with idiopathic short stature

Surgical Outcomes and Predictors of Glucose Metabolism Alterations for Growth Hormone-Secreting Pituitary Adenomas: a Hospital-Based Study of 151 Cases.

Abdominal Adiposity and Total Body Fat as Predictors of Cardiometabolic Health in Children and Adolescents With Obesity

Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly

Serum afamin and its implications in adult growth hormone deficiency: a prospective GH-withdrawal study

Serum Adiponectin Concentration in Relation to Body Fat Distribution and Tissue Insulin Sensitivity in the Glucose Clamp Study

Effect of Growth Hormone Therapy on Liver Enzyme and Other Cardiometabolic Risk Factors in Boys with Obesity and Nonalcoholic Fatty Liver Disease

The association between fat distribution and α1-acid glycoprotein levels among adult females in the United States